114 related articles for article (PubMed ID: 28830893)
1. A typical presentation of a hepatocellular carcinoma in a middle-aged patient.
García Carretero R; Vazquez-Gomez O; Romero Brugera M; Rebollo-Aparicio N
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28830893
[No Abstract] [Full Text] [Related]
2. Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma.
Sacco R; Faggioni L; Bargellini I; Romano A; Bertini M; Ginanni B; Battaglia V; Bertoni M; Bozzi E; Federici G; Metrangolo S; Parisi G; Neri E; Sodini E; Tumino E; Bresci G; Bartolozzi C
J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S234-8. PubMed ID: 22752423
[No Abstract] [Full Text] [Related]
3. Laryngeal metastasis as first presentation of hepatocellular carcinoma.
Hinojar-Gutiérrez A; Nieto-Llanos S; Mera-Menéndez F; Fernández-Contreras ME; Mendoza J; Moreno R
Rev Esp Enferm Dig; 2011 Apr; 103(4):222-4. PubMed ID: 21526881
[No Abstract] [Full Text] [Related]
4. Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.
Tanoglu A; Karagoz E
Asian Pac J Cancer Prev; 2014; 15(2):1063. PubMed ID: 24568452
[No Abstract] [Full Text] [Related]
5. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
Sakai K; Takeda H; Nishijima N; Orito E; Joko K; Uchida Y; Izumi N; Nishio K; Osaki Y
Oncotarget; 2015 Aug; 6(25):21636-44. PubMed ID: 26046304
[TBL] [Abstract][Full Text] [Related]
6. Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.
Elleuch N; Ennaifer R; Romdhane H; Cheikh M; Hefaiedh R; Bougassas W; Ben Nejma H; BelHadj N
Tunis Med; 2015 Jun; 93(6):350-2. PubMed ID: 26644095
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
8. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
9. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
Poullenot F; Bioulac-Sage P; Laumonier H; Saric J; Carteret T; Blanc JF
Acta Oncol; 2014 Mar; 53(3):420-3. PubMed ID: 23713857
[No Abstract] [Full Text] [Related]
10. A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.
Hagihara A; Teranishi Y; Kawamura E; Fujii H; Iwai S; Morikawa H; Enomoto M; Tamori A; Kawada N
Intern Med; 2013; 52(14):1589-92. PubMed ID: 23857091
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.
Chou JW; Cheng KS; Huang CW
Intern Med; 2016; 55(6):623-7. PubMed ID: 26984079
[TBL] [Abstract][Full Text] [Related]
12. Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma.
Knieling F; Waldner MJ; Goertz RS; Strobel D
BMJ Case Rep; 2012 Dec; 2012():. PubMed ID: 23257272
[TBL] [Abstract][Full Text] [Related]
13. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
14. Hepatocellular carcinoma presenting with multiple bone and soft tissue metastases and atypical cytomorphological features--a rare case report.
Rastogi A; Bihari C; Jain D; Gupta NL; Sarin SK
Diagn Cytopathol; 2013 Jul; 41(7):640-3. PubMed ID: 21965139
[TBL] [Abstract][Full Text] [Related]
15. All that glitters: sorafenib.
Abbass K; Dewani S; Markert R; Kaplon MK; Baumann MA
Intern Med; 2011; 50(7):797. PubMed ID: 21467725
[No Abstract] [Full Text] [Related]
16. Spontaneous deep venous thrombosis: An unrecognized entity with sorafenib.
Madabhavi I; Patel A; Anand A; Choudhary M; Revannasiddaiah S
J Cancer Res Ther; 2015; 11(4):1029. PubMed ID: 26881607
[TBL] [Abstract][Full Text] [Related]
17. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.
de Stefano G; Iodice V; Farella N
J Gastrointest Cancer; 2015 Dec; 46(4):430-3. PubMed ID: 25894635
[No Abstract] [Full Text] [Related]
18. Rupture of a Small Hepatocellular Carcinoma in a Stable Disease State in a Patient Receiving Sorafenib Treatment.
Tsuboi R; Asano T; Matsuura K; Asabe S; Mashima H
Chin Med J (Engl); 2018 Apr; 131(8):999-1000. PubMed ID: 29664064
[No Abstract] [Full Text] [Related]
19. [Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
Fabries P; Pauleau G; Brardjanian S; Artéaga C; Guisset M; Coton T
Presse Med; 2013 Feb; 42(2):235-7. PubMed ID: 22425476
[No Abstract] [Full Text] [Related]
20. Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.
Brandi G; De Lorenzo S; Di Girolamo S; Bellentani S; Saccoccio G; Biasco G
Tumori; 2015 Apr; 101(2):e46-8. PubMed ID: 25702656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
